Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

To Launder or Not to Launder: Modelling How the Value of Dirty Income Impacts the Marginal Deterrence of AML Policy

View through CrossRef
Abstract This paper develops a mathematical model of the criminal’s decision to launder money, in order to analyze the relationship between anti-money laundering (AML) policy and the incentive to commit crime. The model includes a measure of the value of dirty income for direct usage in consumption and investment, which is contrasted with the value of laundered money. The results demonstrate that increases in the strictness of AML policy cause criminals to shift away from laundering and towards spending dirty income directly. To the extent that dirty income provides a positive utility on the margin, deterrence effects from AML will be incomplete, as criminals are deterred from crime but not from laundering. Additionally, the value of dirty income is shown to present a confounding influence on the use of changes in money laundering volume to assess criminal welfare. These results suggest that efforts to improve AML regulations may be less effective at combating crime than previously supposed, and highlight the need for further research to understand how criminals use dirty income.
Title: To Launder or Not to Launder: Modelling How the Value of Dirty Income Impacts the Marginal Deterrence of AML Policy
Description:
Abstract This paper develops a mathematical model of the criminal’s decision to launder money, in order to analyze the relationship between anti-money laundering (AML) policy and the incentive to commit crime.
The model includes a measure of the value of dirty income for direct usage in consumption and investment, which is contrasted with the value of laundered money.
The results demonstrate that increases in the strictness of AML policy cause criminals to shift away from laundering and towards spending dirty income directly.
To the extent that dirty income provides a positive utility on the margin, deterrence effects from AML will be incomplete, as criminals are deterred from crime but not from laundering.
Additionally, the value of dirty income is shown to present a confounding influence on the use of changes in money laundering volume to assess criminal welfare.
These results suggest that efforts to improve AML regulations may be less effective at combating crime than previously supposed, and highlight the need for further research to understand how criminals use dirty income.

Related Results

Categorizing Molecular Mutations in MDS and AML
Categorizing Molecular Mutations in MDS and AML
Abstract Introduction: A huge amount of data on genetic alterations has been compiled by high throughput sequencing studies in several hematologic mal...
Clinical and Molecular Characteristics of NPM1MTDe Novo AML ( NPM1MT dnAML) Differ from NPM1MT therapy-associated AML ( NPM1MT tAML)
Clinical and Molecular Characteristics of NPM1MTDe Novo AML ( NPM1MT dnAML) Differ from NPM1MT therapy-associated AML ( NPM1MT tAML)
Background: NPM1-mutated AML accounts for 30% of all adult AML cases and frequently carries a favorable prognostic impact when enriched by a normal karyotype and the absence of FLT...
Low miR‐34c expression is associated with poor outcome in de novo acute myeloid leukemia
Low miR‐34c expression is associated with poor outcome in de novo acute myeloid leukemia
SummaryIntroductionMicroRNA‐34c (miR‐34c) has been found to play important roles in tumorigenesis. However, little is known about miR‐34c expression and the impact on prognosis in ...
ΜΙSΤRG Mice Support Good-Risk AML Engraftment
ΜΙSΤRG Mice Support Good-Risk AML Engraftment
Abstract Introduction Acute myeloid leukemia (AML) is a hematopoietic stem cell derived disease with still unsatisfactory treatment options. Its broad...
ODE-Adefovir As Potential Therapeutic Agent In AML
ODE-Adefovir As Potential Therapeutic Agent In AML
Abstract Adefovir is an antiviral adenosine monophosphate analogue from the class of acyclic nucleoside phosphonate (ANP). During 0n-patent drug library screen, we d...

Back to Top